Johnson & Johnson $JNJ Stock: VestGen Advisors LLC Lowers Position

Key Points

• VestGen Advisors reduced its Johnson & Johnson position by 10.6% in the third quarter, selling 3,775 shares and retaining 31,756 shares valued at approximately $8.4 million. Institutional investors collectively own 69.55% of J&J.
• Analyst sentiment remains favorable, with a consensus rating of “Moderate Buy” and an average price target of $275.92, though individual targets range from $280 to $303.
• J&J exceeded quarterly earnings expectations with $2.59 in EPS and $25.40 billion in revenue, while maintaining a $1.34 quarterly dividend. Shares trade near their 52-week high, and the 2.0% yield comes with a relatively high 81.21% payout ratio.

VestGen Advisors LLC decreased its holdings in shares of Johnson & Johnson (NYSE:JNJ - Free Report) by 10.6% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 31,756 shares of the company's stock after selling 3,775 shares during the quarter. VestGen Advisors LLC's holdings in Johnson & Johnson were worth $8,407,000 at the end of the most recent quarter.

Other hedge funds have also recently added to or reduced their stakes in the company. Jupiter Topco LLC purchased a new stake in Johnson & Johnson in the second quarter worth approximately $1,967,399,000. Corient Private Wealth LP increased its holdings in shares of Johnson & Johnson by 127.3% in the second quarter. Corient Private Wealth LP now owns 6,060,922 shares of the company's stock worth $1,539,292,000 after buying an additional 3,393,981 shares during the period. Wellington Management Group LLP lifted its stake in shares of Johnson & Johnson by 12.5% in the 2nd quarter. Wellington Management Group LLP now owns 22,588,696 shares of the company's stock valued at $5,736,851,000 after acquiring an additional 2,513,321 shares during the last quarter. Amundi boosted its holdings in Johnson & Johnson by 17.5% during the 1st quarter. Amundi now owns 13,406,820 shares of the company's stock valued at $3,277,163,000 after acquiring an additional 2,001,139 shares during the period. Finally, SEB Asset Management AB purchased a new stake in Johnson & Johnson during the 1st quarter valued at about $314,468,000. Institutional investors own 69.55% of the company's stock.

Wall Street Analysts Forecast Growth

Several research firms recently issued reports on JNJ. Argus set a $300.00 target price on Johnson & Johnson in a research note on Wednesday, July 29th. Citigroup increased their target price on Johnson & Johnson from $298.00 to $303.00 and gave the stock a "buy" rating in a research note on Monday, October 5th. JPMorgan Chase & Co. upped their price target on Johnson & Johnson from $270.00 to $285.00 and gave the company a "neutral" rating in a report on Tuesday, September 29th. Wells Fargo & Company boosted their price target on Johnson & Johnson from $275.00 to $287.00 and gave the company an "overweight" rating in a research note on Friday, October 16th. Finally, Royal Bank Of Canada lowered their target price on Johnson & Johnson from $290.00 to $280.00 and set an "outperform" rating on the stock in a research report on Wednesday, October 14th. One research analyst has rated the stock with a Strong Buy rating, seventeen have issued a Buy rating and eight have assigned a Hold rating to the company's stock. According to data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and an average target price of $275.92.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $273.39 on Friday. Johnson & Johnson has a 52-week low of $185.12 and a 52-week high of $282.02. The company has a quick ratio of 0.74, a current ratio of 1.02 and a debt-to-equity ratio of 0.44. The firm's fifty day moving average is $265.74 and its 200 day moving average is $246.94. The company has a market cap of $658.13 billion, a price-to-earnings ratio of 41.42, a PEG ratio of 2.72 and a beta of 0.21.

Johnson & Johnson (NYSE:JNJ - Get Free Report) last issued its quarterly earnings data on Tuesday, October 13th. The company reported $2.59 EPS for the quarter, topping analysts' consensus estimates of $2.53 by $0.06. Johnson & Johnson had a net margin of 16.20% and a return on equity of 31.64%. The business had revenue of $25.40 billion during the quarter, compared to analysts' expectations of $25.38 billion. During the same period last year, the company posted $2.80 EPS. The business's revenue was up 5.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.050-11.150 EPS. Sell-side analysts forecast that Johnson & Johnson will post 11.12 EPS for the current fiscal year.

Johnson & Johnson Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.34 dividend. The ex-dividend date of this dividend is Tuesday, November 24th. This represents a $5.36 annualized dividend and a dividend yield of 2.0%. Johnson & Johnson's dividend payout ratio is currently 81.21%.

Insider Buying and Selling

In other news, EVP Timothy Schmid sold 33,597 shares of the business's stock in a transaction on Wednesday, September 2nd. The shares were sold at an average price of $274.74, for a total transaction of $9,230,439.78. Following the completion of the sale, the executive vice president directly owned 25,447 shares of the company's stock, valued at approximately $6,991,308.78. The trade was a 56.90% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Jennifer L. Taubert sold 15,000 shares of the stock in a transaction that occurred on Monday, August 17th. The stock was sold at an average price of $263.36, for a total value of $3,950,400.00. Following the completion of the transaction, the executive vice president directly owned 194,451 shares in the company, valued at approximately $51,210,615.36. This trade represents a 7.16% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 64,515 shares of company stock valued at $17,271,766 in the last ninety days. 0.16% of the stock is owned by company insiders.

Johnson & Johnson News Roundup

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Icotyde, J&J’s oral plaque-psoriasis treatment, is reportedly gaining traction among U.S. dermatologists and being prescribed earlier in the treatment process. Strong adoption could support pharmaceutical growth and help offset declines in older products. Does Johnson & Johnson Have a New Edge in Plaque Psoriasis?
• Positive Sentiment: J&J presented 26 abstracts at TCT 2026 supporting the safety, efficacy and cost-effectiveness of its Impella heart pumps. The data may strengthen the long-term outlook for the MedTech portfolio despite recent weakness. Johnson & Johnson Presents Impella Data at TCT 2026
• Positive Sentiment: J&J continues to be highlighted as a dependable dividend stock, supported by more than five decades of annual payout increases. That income profile can provide downside support for long-term investors. Dividend Kings With 50-Plus Years of Payout Increases
• Neutral Sentiment: J&J’s recent performance has been strong, with shares reportedly up 42% over the past year, helped by progress toward resolving talc litigation and growth from newer medicines. Analysts are debating whether that advance has already priced in much of the improvement. Johnson & Johnson Is Up 42% in a Year
• Neutral Sentiment: Broker sentiment remains generally favorable, but the article questions how much weight investors should place on consensus recommendations as J&J trades near its 52-week high and at an elevated earnings multiple. Johnson & Johnson Broker Ratings
• Negative Sentiment: MedTech growth slowed in the third quarter because of international-market challenges and weakness at Abiomed. Investors may be concerned that a rebound in the fourth quarter will not fully offset the segment’s short-term disappointment. JNJ MedTech Segment Disappoints in Q3
• Negative Sentiment: Analysts see potential earnings pressure in 2027, while the market is already assigning a premium valuation after strong gains. That combination increases the risk of profit-taking if growth slows. Johnson & Johnson Strong Q3 Growth, but 2027 Could Test Earnings
• Negative Sentiment: Pomerantz announced an investigation into potential claims on behalf of J&J investors. Although such announcements do not establish wrongdoing, they add headline and litigation risk. Pomerantz Investor Investigation

Johnson & Johnson Profile

Johnson & Johnson NYSE: JNJ is a global healthcare company headquartered in New Brunswick, New Jersey. Founded in 1886, the company develops and markets products and services for patients, healthcare professionals and institutions worldwide.

Johnson & Johnson operates through two principal segments: Innovative Medicine and MedTech. Innovative Medicine focuses on pharmaceuticals for areas such as immunology, oncology, neuroscience, infectious diseases and cardiovascular conditions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.